"10.1371_journal.pone.0121300","plos one","2015-03-26T00:00:00Z","Sven-Erik Olofsson; Björn Nodin; Alexander Gaber; Jakob Eberhard; Mathias Uhlén; Karin Jirström; Mats Jerkeman","Department of Clinical Sciences, Division of Oncology and Pathology, Lund University, Skåne University Hospital, Lund, Sweden; Science for Life Laboratory and School of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden; School of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden","Conceived and designed the experiments: KJ JE MJ. Performed the experiments: SEO BN KJ. Analyzed the data: SEO KJ AG. Contributed reagents/materials/analysis tools: MU. Wrote the paper: SEO KJ MJ.","JE and KJ are co-inventors of two patents related to the use of RBM3 as a prognostic biomarker in testicular cancer: 1) RBM3 protein in testicular cancer diagnostics and prognostics EU Patent no. (EP)2396659, validated in Denmark, France, Ireland, Nederlands, Schweiz, Great Britain, Sweden and Germany. Australia Patent no. (AU)2010212769. There are patents pending in Japan (2011-549603), Canada (2749349) and USA (13/210809). 2) Prediction of response to platinum-based therapy. EU Patent no. (EP)2396660, validated in Denmark, France, Ireland, Nederlands, Schweiz, Great Britain, Sweden and Germany. Australia Patent no. (AU)2010212772, USA Patent no. (US)8747910. There are patents pending in Brazil (PI1008875-0), Hong Kong (12107047.4), Japan (2011-549604), Canada (2749350) and China (201080007960.0). This does not alter the authors adherence to all PLOS ONE policies on sharing data and material. The remaining authors have declared that no competing interests exist.","2015","03","Sven-Erik Olofsson","SEO",7,FALSE,3,3,3,3,TRUE,TRUE,FALSE,0,NA,FALSE
